75 results on '"Opelz, G."'
Search Results
2. Donor organ intervention before kidney transplantation: Head-to-head comparison of therapeutic hypothermia, machine perfusion, and donor dopamine pretreatment. What is the evidence?
- Author
-
Schnuelle P, Drüschler K, Schmitt WH, Benck U, Zeier M, Krämer BK, and Opelz G
- Subjects
- Female, Graft Survival, Humans, Male, Middle Aged, Dopamine administration & dosage, Evidence-Based Medicine, Hypothermia, Induced adverse effects, Kidney Transplantation, Perfusion methods, Tissue Donors
- Abstract
Therapeutic hypothermia, hypothermic pulsatile machine perfusion (MP), and renal-dose dopamine administered to stable brain-dead donors have shown efficacy to reduce the dialysis requirement after kidney transplantation. In a head-to-head comparison of the three major randomized controlled trials in this field, we estimated the number-needed-to-treat for each method, evaluated costs and inquired into special features regarding long-term outcomes. The MP and hypothermia trials used any dialysis requirement during the first postoperative week, whereas the dopamine trial assessed >1 dialysis session as primary endpoint. Compared to controls, the respective rates declined by 5.7% with MP, 10.9% with hypothermia, and 10.7% with dopamine. Costs to prevent one endpoint in one recipient amount to approximately $17 000 with MP but are negligible with the donor interventions. MP resulted in a borderline significant difference of 4% in 3-year graft survival, but a point of interest is that the preservation method was switched in 25 donors (4.6%) for technical reasons. Graft survival was not improved with dopamine on intention-to-treat but suggested an exposure-response relationship with infusion time. MP was less efficacious and cost-effective to prevent posttransplant dialysis. Whether the benefit on early graft dysfunction achieved with any method will improve long-term graft survival remains to be established., (© 2019 The American Society of Transplantation and the American Society of Transplant Surgeons.)
- Published
- 2019
- Full Text
- View/download PDF
3. Changes of NK cell subsets with time post-transplant in peripheral blood of renal transplant recipients.
- Author
-
Zhu L, Aly M, Wang H, Karakizlis H, Weimer R, Morath C, Kuon RJ, Toth B, Ekpoom N, Opelz G, and Daniel V
- Subjects
- Adult, Aged, Cell Separation, Cytotoxicity, Immunologic, Female, Flow Cytometry, Humans, Immunomodulation, Immunophenotyping, Male, Middle Aged, Transplantation, Homologous, Graft Rejection immunology, Kidney Transplantation, Killer Cells, Natural immunology, Lymphocyte Subsets immunology, Postoperative Complications immunology
- Abstract
Background: There is evidence that NK cells with low cytotoxicity but strong immunoregulatory characteristics contribute to good graft outcome. We attempted to investigate which NK cell subsets increase post-transplant and might affect graft function., Method: Lymphocyte and NK cell subsets were determined in whole blood using eight-colour-fluorescence flow cytometry in patients pre-transplant and post-transplant. In total, 31 transplant recipients were studied., Results: When cell numbers were compared in 9 patients pre- and 6 months post-transplant, post-transplant CD56dimCD16+ (p = 0.011) NK cells with the phenotype CD158a+ (p = 0.008), CD158e+ (p = 0.038), NKG2A+ (p = 0.008), NKG2D+ (p = 0.011), IFNyR+ (p = 0.008), perforin+ (p = 0.008), granzymeB+ (p = 0.008), perforin+granzymeB+ (p = 0.008) and perforin-granzymeB- (p = 0.021) were lower than those pre-transplant, indicating a post-transplant reduction of cytotoxic NK cells. In 28 patients NK cell subsets were analyzed with respect to time post-transplant (median 888 days post-transplant). CD56dimCD16+ NK cells co-expressing CD158a (p = 0.014), NKG2D (p = 0.047), IL4R (p = 0.038), IL10R (p = 0.008) and IFNy (p = 0.036) as well as CD56bright NK cells with the phenotype TGFß+ (p = 0.017), TGFR+ (p = 0.035), CD158a+ (p = 0.042) and perforin-granzymeB- (p = 0.048) increased with time post-transplant., Conclusion: Post-transplant, cytotoxic NK cells were lower than pre-transplant and remained low, whereas NK cell subsets with potentially immunoregulatory properties increased., (Copyright © 2018 Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
4. Long- and short-term outcomes in renal allografts with deceased donors: A large recipient and donor genome-wide association study.
- Author
-
Hernandez-Fuentes MP, Franklin C, Rebollo-Mesa I, Mollon J, Delaney F, Perucha E, Stapleton C, Borrows R, Byrne C, Cavalleri G, Clarke B, Clatworthy M, Feehally J, Fuggle S, Gagliano SA, Griffin S, Hammad A, Higgins R, Jardine A, Keogan M, Leach T, MacPhee I, Mark PB, Marsh J, Maxwell P, McKane W, McLean A, Newstead C, Augustine T, Phelan P, Powis S, Rowe P, Sheerin N, Solomon E, Stephens H, Thuraisingham R, Trembath R, Topham P, Vaughan R, Sacks SH, Conlon P, Opelz G, Soranzo N, Weale ME, and Lord GM
- Subjects
- Adult, DNA Replication, Female, Genotype, Graft Survival immunology, Histocompatibility Testing, Humans, Male, Middle Aged, Polymorphism, Single Nucleotide, Transplantation, Homologous, Genome-Wide Association Study, Kidney Transplantation, Tissue Donors, Transplant Recipients
- Abstract
Improvements in immunosuppression have modified short-term survival of deceased-donor allografts, but not their rate of long-term failure. Mismatches between donor and recipient HLA play an important role in the acute and chronic allogeneic immune response against the graft. Perfect matching at clinically relevant HLA loci does not obviate the need for immunosuppression, suggesting that additional genetic variation plays a critical role in both short- and long-term graft outcomes. By combining patient data and samples from supranational cohorts across the United Kingdom and European Union, we performed the first large-scale genome-wide association study analyzing both donor and recipient DNA in 2094 complete renal transplant-pairs with replication in 5866 complete pairs. We studied deceased-donor grafts allocated on the basis of preferential HLA matching, which provided some control for HLA genetic effects. No strong donor or recipient genetic effects contributing to long- or short-term allograft survival were found outside the HLA region. We discuss the implications for future research and clinical application., (© 2018 The Authors. American Journal of Transplantation published by Wiley Periodicals, Inc. on behalf of The American Society of Transplantation and the American Society of Transplant Surgeons.)
- Published
- 2018
- Full Text
- View/download PDF
5. Association of pre- and early post-transplant serum amino acids and metabolites of amino acids and liver transplant outcome.
- Author
-
Oweira H, Lahdou I, Opelz G, Daniel V, Terness P, Schmidt J, Mehrabi A, Fusch G, Schefold J, Zidan A, and Sadeghi M
- Subjects
- Adult, Female, Graft Rejection mortality, Graft Survival, Humans, Male, Middle Aged, Risk Factors, Survival Analysis, Amino Acids blood, Bilirubin blood, End Stage Liver Disease therapy, Graft Rejection diagnosis, Liver Transplantation, Sex Factors
- Abstract
The aim of the present study was to investigate association of serum amino (AA) acids and metabolites of AAs with post-transplant outcome in liver transplant recipients. Eighty-nine patients with end-stage liver diseases and available pre- and early post-transplant serum were characterised as patients with (GI) and without one-year mortality (GII) and patients with and without early graft dysfunction (EAD). A panel of pre- and early post-transplant serum levels of AAs and early and metabolites of tryptophan were measured using tandem mass spectrometry. Patient groups had significantly higher pre-transplant serum levels of phenylalanine, tryptophan, and tryptophan metabolites than healthy controls (for all p<0.001). Pre-transplant serum levels of all these parameters were significantly higher in GI than in GII (for all p<0.001). GI had a higher MELD score and re-transplantation number than GII (p≤0.005 for both investigations). Serum bilirubin on day 5 and serum phenylalanine on day 10 post-transplant were associated parameters of mortality, whereas day 1post-transplant phenylalanine and kynurenine and female gender were associated parameters of EAD. Our results indicate that pre- and early post-transplant levels of phenylalanine, tryptophan and metabolites of tryptophan are increased in patients and are associated with EAD and one-year mortality in liver transplant recipients., (Copyright © 2018 Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
6. Low utility of serum 25-hydroxyvitamin D 3 and 1, 25-dihydroxyvitamin D 3 in predicting peripheral Treg and Th17 cell counts in ESRD and renal transplant patients.
- Author
-
Aly MG, Zhu L, Weimer R, Opelz G, Morath C, Kuon R, Tohamy M, Saadi G, Soliman M, Ibrahim W, and Daniel V
- Subjects
- Adult, CD4 Lymphocyte Count, Calcifediol immunology, Calcitriol immunology, Cytokines immunology, Female, Humans, Kidney Failure, Chronic immunology, Kidney Failure, Chronic surgery, Male, Middle Aged, T-Lymphocytes, Regulatory immunology, T-Lymphocytes, Regulatory pathology, Th17 Cells immunology, Th17 Cells pathology, Calcifediol blood, Calcitriol blood, Kidney Failure, Chronic blood, Kidney Transplantation, T-Lymphocytes, Regulatory metabolism, Th17 Cells metabolism
- Abstract
Background: Vitamin D has shown an immune-modulatory effect in different studies. Vitamin D stimulates Tregs and inhibits Th17 cells. The immune-modulatory role of vitamin D in chronic kidney disease (CKD) and renal transplant patients is unclear. We measured whether different serum levels of vitamin D were associated with an increased or decreased presence of lymphocyte subsets including Treg and Th17 cells in end-stage renal disease (ESRD) and renal transplant recipients., Methods: Eighty-seven renal transplant recipients and 53 end-stage renal disease (ESRD) patients were enrolled in this study. The absolute counts of CD4+ and CD8+ T, CD16+ CD56+ NK, CD19+ B, CD4+ CD25+ CD127- Foxp3+ (Tregs), Helios+ Tregs, CD38+ Tregs, and CD4+ CD17+ (Th17) cells were analyzed in peripheral blood in both patient groups. In addition, serum 25 (OH) D
3 , 1, 25 (OH)2 D3 , IL-6, IL-17, IL-23, and TGF-β1 were measured. The association between lymphocyte subset counts and 1, 25 (OH)2 D3 or 25 (OH) D3 was studied, as was the association between serum IL-6, IL-17, IL-23, or TGF-β1 and 1,25 (OH)2 D3 or 25 (OH) D3 ., Results: Serum 25 (OH) D3 and 1,25 (OH)2 D3 levels were not independently associated with peripheral CD4+ T, CD19+ B, CD16+ CD56+ NK, Treg, or Th17 cell counts. In contrast to serum 25 (OH) D3 , serum1, 25 (OH)2 D3 was positively associated with CD8+ T cells counts in renal transplant recipients., Conclusion: Our findings indicate low utility of serum 25 (OH) D3 and 1, 25 (OH)2 D3 levels in predicting a change in lymphocyte subset counts in ESRD and renal transplant patients., (Copyright © 2017 Elsevier B.V. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
7. IFNy+ and IFNy- Treg subsets with stable and unstable Foxp3 expression in kidney transplant recipients with good long-term graft function.
- Author
-
Trojan K, Unterrainer C, Aly M, Zhu L, Weimer R, Bulut N, Morath C, Opelz G, and Daniel V
- Abstract
Background: Treg are a heterogenous cell population. In the present study we attempted to identify Treg subsets that might contribute to stable and good long-term graft function., Method: Lymphocyte and Treg subsets were studied in 136 kidney transplant recipients with good long-term graft function and in 52 healthy control individuals using eight-color-fluorescence flow cytometry. Foxp3 TSDR methylation status was investigated in enriched IFNy+ and IFNy- Treg preparations using high resolution melt analysis., Results: Compared with healthy controls, patients showed strong associations of IFNy secreting Helios+ and Helios- Treg with Treg that co-expressed perforin and/or CTLA4 (CD152; p<0.01). Moreover they showed associations of IFNy-Helios+ Treg with Treg that produced TGFβ and/or perforin and of IFNy-Helios- Treg with TGFβ production (all p<0.01). Only in patients, but not in healthy controls, were IFNy- Helios+ and Helios- Treg associated with higher CD45+, CD3+, (CD4+), CD19+ lymphocyte counts (p<0.001). In addition IFNy-Helios+ Treg were associated with CD16+56+ lymphocytes (p<0.001). Enriched IFNy- Treg from female but not male patients showed an association of Foxp3 methylation with higher total Treg and higher Helios+IFNy-, CXCR3+Lselectin+ (CD183+CD62L+), CXCR3-Lselectin+ and CD28+HLADR+ Treg subsets (p<0.01). Enriched IFNy+ Treg from male patients showed an association of demethylated Foxp3 with total Treg and IL10-TFGβ+ Treg counts, and in enriched IFNy- Treg an association of methylated Foxp3 with APO1/FasR+FasL+ (CD95+CD178+) Treg (p<0.01)., Conclusions: Kidney recipients with good long-term graft function possess IFNy+ and IFNy- Treg with stable and unstable Foxp3 expression in the blood. They co-express CD28, HLADR, CTLA4, CXCR3, Lselectin, TGFβ, perforin and FasL and might contribute to the establishment and maintenance of good long-term graft function., (Copyright © 2016. Published by Elsevier B.V.)
- Published
- 2016
- Full Text
- View/download PDF
8. Association between steroid dosage and death with a functioning graft after kidney transplantation.
- Author
-
Opelz G and Döhler B
- Subjects
- Adolescent, Adult, Anti-Inflammatory Agents administration & dosage, Anti-Inflammatory Agents adverse effects, Cardiovascular Diseases etiology, Female, Graft Rejection etiology, Humans, Immunosuppressive Agents therapeutic use, Infections etiology, International Agencies, Kidney Failure, Chronic complications, Kidney Failure, Chronic mortality, Male, Middle Aged, Prednisone administration & dosage, Retrospective Studies, Survival Rate, Young Adult, Cardiovascular Diseases mortality, Graft Rejection mortality, Graft Survival drug effects, Infections mortality, Kidney Failure, Chronic therapy, Kidney Transplantation mortality, Prednisone adverse effects
- Abstract
Death with a functioning graft remains a major challenge following kidney transplantation. Steroid dosing may be a modifiable risk factor. Collaborative Transplant Study (CTS) data were analyzed to assess the relationship between long-term steroid dose and death with function during years 2-5 posttransplant in 41 953 adult recipients of a deceased-donor kidney transplant during 1995-2010. Steroid dose at year 1 correlated significantly with death with function overall, and with death due to cardiovascular disease or infection (all p < 0.001). In patients with optimal graft function (serum creatinine <130 µmol/L) and no anti-rejection treatment during (a) year 1 (b) years 1 and 2, these significant associations remained (all p < 0.001). The center-specific incidence of steroid withdrawal during year 2 showed a significant inverse association with death due to cardiovascular disease (p < 0.001) or infection (p < 0.001) overall, and within the subpopulation with good graft function and no rejection during year 1 (p = 0.002 and p < 0.001, respectively). Maintenance steroid dose shows a highly significant association with death with a functioning graft caused by cardiovascular disease or infection during years 2-5 after kidney transplantation, even in patients with good graft outcomes in whom steroid treatment would appear to be unnecessary., (© Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons.)
- Published
- 2013
- Full Text
- View/download PDF
9. Influence of test technique on sensitization status of patients on the kidney transplant waiting list.
- Author
-
Gombos P, Opelz G, Scherer S, Morath C, Zeier M, Schemmer P, and Süsal C
- Subjects
- Antibody Specificity, Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Humans, Isoantibodies blood, Male, Tissue Donors, Waiting Lists, HLA Antigens immunology, Histocompatibility Testing, Isoantibodies immunology, Kidney Transplantation immunology
- Abstract
The exquisitely sensitive single antigen bead (SAB) technique was shown to detect human leukocyte antigen (HLA) antibodies in sera of healthy male blood donors. Such false reactions can have an impact on critical decisions, especially with respect to the determination of unacceptable HLA-antigen mismatches in patients awaiting a kidney transplant. We tested pretransplant sera of 534 patients on the kidney waiting list using complement-dependent cytotoxicity (CDC), enzyme-linked immunosorbent assay (ELISA) and SAB in parallel. Evidence of HLA antibodies was obtained in 5% of patients using CDC, 14% using ELISA, and 81% using SAB. Among patients without history of an immunizing event, 77% showed evidence of HLA antibodies in SAB. In contrast 98% of these patients were negative in ELISA and CDC. In patients without an immunizing event, SAB-detected antibodies reacted not always weakly but with mean fluorescence intensity (MFI) values as high as 14 440. High-MFI-value antibodies were found in some of these patients with HLA specificities that are rather common in general population, consideration of which would lead to unjustified exclusion of potential kidney donors. False SAB reactions can be unveiled by testing with additional antibody assays. Denial of donor kidneys to recipients based on HLA-antibody specificities detected exclusively in the SAB assay is not advisable., (© Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons.)
- Published
- 2013
- Full Text
- View/download PDF
10. No impact of KIR-ligand mismatch on allograft outcome in HLA-compatible kidney transplantation.
- Author
-
Tran TH, Unterrainer C, Fiedler G, Döhler B, Scherer S, Ruhenstroth A, Adamek M, Middleton D, and Opelz G
- Subjects
- Adolescent, Adult, Aged, Cohort Studies, Female, Genotype, Graft Survival, Histocompatibility Testing, Humans, Ligands, Male, Middle Aged, Proportional Hazards Models, Renal Insufficiency surgery, Risk Factors, Time Factors, Young Adult, Histocompatibility Antigens Class I genetics, Kidney Transplantation methods, Receptors, KIR metabolism, Renal Insufficiency immunology
- Abstract
Natural killer (NK) cell function can be modulated by the killer cell immunoglobulin-like receptors (KIR) which interact with human leukocyte antigen (HLA) class I molecules on target cells. KIR-ligand mismatching has recently been shown by van Bergen et al. (American Journal of Transplantation 2011; 11(9): 1959-1964) to be a significant risk factor for long-term graft loss in HLA-A, -B and -DR compatible kidney transplants. To verify this potentially important finding, we performed genotyping of 608 deceased-donor kidney graft recipients and their HLA-A, -B and -DR compatible donors for KIR and HLA, using samples and clinical data provided by the Collaborative Transplant Study. Graft survival of KIR-ligand-matched and -mismatched transplants was compared. We found no impact of KIR-ligand mismatching on 10-year graft survival in HLA-A, -B, -DR compatible kidney transplants. Further analysis did not reveal a significant effect of recipient activating/inhibitory KIR or KIR genotypes on graft survival. Our data do not support the concept that KIR-HLA matching might serve as a tool to improve long-term renal allograft survival., (© Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons.)
- Published
- 2013
- Full Text
- View/download PDF
11. Association of HLA mismatch with death with a functioning graft after kidney transplantation: a collaborative transplant study report.
- Author
-
Opelz G and Döhler B
- Subjects
- Adolescent, Adult, Bacterial Infections etiology, Bacterial Infections physiopathology, Cadaver, Cardiovascular Diseases etiology, Cardiovascular Diseases physiopathology, Cohort Studies, Confidence Intervals, Databases, Factual, Female, Follow-Up Studies, Germany, Graft Survival, Humans, Kidney Failure, Chronic diagnosis, Kidney Failure, Chronic surgery, Kidney Transplantation mortality, Male, Middle Aged, Proportional Hazards Models, Retrospective Studies, Risk Assessment, Survival Analysis, Young Adult, Bacterial Infections mortality, Cardiovascular Diseases mortality, Cause of Death, HLA Antigens immunology, Histocompatibility Testing, Kidney Transplantation immunology
- Abstract
HLA mismatches may correlate with risk of death with a functioning graft (DWFG) because of requirement for higher immunosuppression doses and more antirejection therapy. Deceased-donor kidney transplants (n = 177 584) performed 1990-2009 and reported to the Collaborative Transplant Study were analyzed. The incidence of DWFG was found to be 4.8% during year 1 posttransplant and 7.7% during years 2-5 (Kaplan-Meier estimates). Most frequent causes of DWFG were infection, cardiovascular disease and malignancy (32.2%, 30.9% and 3.6% in year 1; 16.4%, 29.6% and 15.9% in years 2-5). HLA-A + B + DR mismatches were significantly associated with DWFG during year 1 (p < 0.001), a correlation that diminished but persisted during years 2-5 (p < 0.001). HLA mismatch was associated with DWFG because of infection (p < 0.001 during year 1, p = 0.043 during years 2-5) or cardiovascular disease (p < 0.001 during year 1, p = 0.030 during years 2-5) but not malignancy. There was also a significant association between HLA mismatch and hospitalization for viral (p < 0.001) or bacterial (p = 0.002) infection. Multivariable analysis showed that mismatches for HLA class II were more strongly associated with both hospitalization and DWFG than mismatches for HLA class I., (© Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons.)
- Published
- 2012
- Full Text
- View/download PDF
12. CD4(+)CD25(+)Foxp3(+)IFNγ(+) Treg are immunosuppressive in vitro and increase with intensity of the alloresponse in pretransplant MLC.
- Author
-
Daniel V, Sadeghi M, Wang H, and Opelz G
- Subjects
- CD4 Antigens metabolism, Cells, Cultured, Forkhead Transcription Factors metabolism, Humans, Immunity, Cellular, Immunosuppression Therapy, Interleukin-2 Receptor alpha Subunit metabolism, Isoantigens immunology, Lymphocyte Count, Lymphocyte Culture Test, Mixed, Interferon-gamma metabolism, Kidney Transplantation immunology, Perioperative Period, T-Lymphocyte Subsets immunology, T-Lymphocytes, Regulatory immunology
- Abstract
IFNγ-producing CD3(+)CD4(+)CD25(+)Foxp3(+) induced Treg are more frequently detectable in patients with good than in patients with impaired long-term kidney graft function. We investigated the in-vitro function of separated CD3(+)CD4(+)CD25(+)Foxp3(+)IFNγ(+) PBL that were induced by phorbol-12-myristate-13-acetate(PMA)/Ionomycin or alloantigenic stimulation. Additionally, we studied iTreg induction and cell proliferation in MLC with pretransplant obtained PBL. CD4(+)CD25(+)IFNγ(+) PBL separated from PMA/Ionomycin-stimulated PBL of healthy controls inhibited secondary cell cultures of autologous PBL. Furthermore, CD4(+)CD25(+)IFNγ(+) PBL separated from primary MLC and added to secondary MLC suppressed allogeneic T-cell activation in secondary MLC unspecifically, irrespective of the stimulator cell. However, the strongest suppression was observed in specific MLC. Patients with poor long-term graft outcome were able to form IFNγ(+) iTreg in pretransplant MLC. Eight patients with a serum creatinine level ranging from 0.9 to 14 mg/dl 18-29 years posttransplant were studied. In MLC with pretransplant obtained recipient and donor cells, strong IFNγ(+) iTreg (p=0.007) and strong blast induction (p=0.047) were associated with impaired long-term graft outcome. Long-term graft outcome was not associated with cell proliferation and iTreg induction in unspecific MLC with third-party cells as stimulator. The data indicate that patients with impaired long-term graft outcome are able to form high numbers of IFNγ(+) iTreg in specific pretransplant MLC. Quantity of induced IFNγ(+) iTreg depends on the strength of the alloresponse and both parameters are inversely associated with long-term graft outcome., (Copyright © 2012 Elsevier B.V. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
13. Posttransplant sCD30 as a biomarker to predict kidney graft outcome.
- Author
-
Süsal C and Opelz G
- Subjects
- Animals, Biomarkers analysis, Graft Rejection prevention & control, Humans, Immunosuppressive Agents therapeutic use, Predictive Value of Tests, Treatment Outcome, Graft Survival, Ki-1 Antigen blood, Kidney Transplantation adverse effects
- Abstract
In current clinical praxis, monitoring of immunosuppressive agents in organ transplantation is restricted to measurement of drug blood levels and does not consider the drug's variable effect on the individual patient's immune system. Establishment of biological markers that measure the biological effect of immunosuppressive drugs is desirable and would enable the identification of patients who are at risk of developing rejection, or patients who are suitable for minimization or weaning of immunosuppressive therapy. Several studies demonstrated that the technically simple posttransplant measurement in serum of the T cell activation marker soluble CD30 (sCD30) allows prediction of subsequent graft loss in kidney transplant recipients. sCD30 is a relatively large molecule and therefore an attractive biological marker which is resistant to repeated thawing cycles and temperature differences and easily determined using commercial ELISA. Whether sCD30-based prospective adjustment of immunosuppressive therapy can prevent irreversible graft damage and improve long-term graft outcome awaits evaluation in randomized controlled trials., (Copyright © 2011 Elsevier B.V. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
14. Living kidney donor follow-up: state-of-the-art and future directions, conference summary and recommendations.
- Author
-
Leichtman A, Abecassis M, Barr M, Charlton M, Cohen D, Confer D, Cooper M, Danovitch G, Davis C, Delmonico F, Dew MA, Garvey C, Gaston R, Gill J, Gillespie B, Ibrahim H, Jacobs C, Kahn J, Kasiske B, Kim J, Lentine K, Manyalich M, Medina-Pestana J, Merion R, Moxey-Mims M, Odim J, Opelz G, Orlowski J, Rizvi A, Roberts J, Segev DL, Sledge T, Steiner R, Taler S, Textor S, Thiel G, Waterman A, Williams E, Wolfe R, Wynn J, and Matas AJ
- Subjects
- Congresses as Topic, Follow-Up Studies, Humans, Kidney Transplantation standards, Living Donors psychology, Living Donors statistics & numerical data
- Abstract
In light of continued uncertainty regarding postkidney donation medical, psychosocial and socioeconomic outcomes for traditional living donors and especially for donors meeting more relaxed acceptance criteria, a meeting was held in September 2010 to (1) review limitations of existing data on outcomes of living kidney donors; (2) assess and define the need for long-term follow-up of living kidney donors; (3) identify the potential system requirements, infrastructure and costs of long-term follow-up for living kidney donor outcomes in the United States and (4) explore practical options for future development and funding of United States living kidney donor data collection, metrics and endpoints. Conference participants included prior kidney donors, physicians, surgeons, medical ethicists, social scientists, donor coordinators, social workers, independent donor advocates and representatives of payer organizations and the federal government. The findings and recommendations generated at this meeting are presented., (©Copyright 2011 The American Society of Transplantation and the American Society of Transplant Surgeons.)
- Published
- 2011
- Full Text
- View/download PDF
15. Treatment of kidney transplant recipients with ACEi/ARB and risk of respiratory tract cancer: a collaborative transplant study report.
- Author
-
Opelz G and Döhler B
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Neoplasms chemically induced, Proportional Hazards Models, Angiotensin Receptor Antagonists adverse effects, Angiotensin-Converting Enzyme Inhibitors adverse effects, Kidney Transplantation adverse effects, Respiratory Tract Neoplasms chemically induced, Smoking adverse effects
- Abstract
Whether treatment with angiotensin-converting enzyme inhibitors (ACEi) and/or angiotensin receptor blockers (ARB) increases the risk of cancer is controversial. Collaborative transplant study data were analyzed according to whether kidney transplant recipients were treated with ACEi/ARB at year 1. Twenty-four thousand and ninety patients were studied of whom 9079 (38%) patients received ACEi/ARB. There were 872 nonskin malignancies during years 2-8 posttransplant, including 107 respiratory/intrathoracic tumors. The standardized incidence ratio (SIR) for all nonskin malignancies was similar between the ACEi/ARB (1.91) and no ACEi/ARB (1.81) groups (p = 0.42). For respiratory/intrathoracic tumors, however, SIR was significantly higher with ACEi/ARB (1.65 vs. 1.09 for no ACEi/ARB, p = 0.033). Multivariate Cox regression analysis showed that ACEi/ARB treatment was not associated with an increased risk of respiratory/intrathoracic tumors in nonsmokers. In patients with a history of smoking, however, the risk of respiratory/intrathoracic tumors was 2.77 (95% CI 1.19-6.43, p = 0.018) in patients without ACEi/ARB treatment as compared to 7.10 (95% CI 3.27-15.4, p < 0.001) in patients treated with ACEi/ARB. Our data indicate that in kidney transplant recipients, ACEi/ARB treatment is associated with a significant increase in the rate of respiratory/intrathoracic tumors in the subpopulation of patients with a history of smoking., (©2011 The Authors Journal compilation © 2011 The American Society of Transplantation and the American Society of Transplant Surgeons.)
- Published
- 2011
- Full Text
- View/download PDF
16. Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma.
- Author
-
Stern M, Opelz G, Döhler B, and Hess C
- Subjects
- Adolescent, Adult, Aged, Child, Child, Preschool, Cohort Studies, Female, Genotype, Heart Transplantation, Humans, Kidney Transplantation, Killer Cells, Natural pathology, Liver Transplantation, Lymphoma, Non-Hodgkin pathology, Lymphoma, Non-Hodgkin therapy, Male, Middle Aged, Polymerase Chain Reaction, Survival Rate, Young Adult, Interferon-gamma genetics, Lymphoma, Non-Hodgkin genetics, Polymorphism, Single Nucleotide genetics, Receptors, IgG genetics, Receptors, KIR genetics, Receptors, KIR3DL2 genetics
- Abstract
Posttransplantation non-Hodgkin lymphoma is a life-threatening complication after transplantation. Although pharmacologically suppressed adaptive immunity plays a major role in its development, the role of innate immunity in posttransplantation lymphoma is unknown. We assessed the 158 V/F polymorphism in the Fc-gamma receptor 3A gene (FCGR3A), killer cell immunoglobulin-like receptor (KIR) genotype, KIR ligand status, and a single nucleotide polymorphism affecting the production of interferon-gamma (IFN-gamma; +874 A/T) in 236 patients with posttransplantation lymphoma reported to the Collaborative Transplant Study. In addition, polymorphisms in the interleukin-10 (IL-10) and transforming growth factor-beta (TGF-beta) genes previously associated with lymphoma development were also typed. Using a split-cohort approach, gene/allele frequency was related to the 5-year patient survival after the diagnosis of lymphoma and compared with 100 control solid organ transplant recipients. FCGR3A and KIR genotype significantly influenced survival after diagnosis of posttransplantation lymphoma: the hazard of dying was reduced in homozygous carriers of the high-affinity V allele (hazard ratio 0.49, 95% confidence interval 0.29-0.82, P = .006), whereas carrying a genotype including KIR2DL2/KIR2DS2 increased the risk of dying (hazard ratio 1.49, 95% confidence interval 1.07-2.05, P = .02). KIR ligands and cytokine polymorphisms had no effect on survival. None of the genetic loci analyzed emerged as risk factors for lymphoma development.
- Published
- 2010
- Full Text
- View/download PDF
17. Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells.
- Author
-
Fuchs D, Daniel V, Sadeghi M, Opelz G, and Naujokat C
- Subjects
- Cell Line, Tumor, Humans, ATP-Binding Cassette Transporters metabolism, Drug Resistance, Multiple drug effects, Drug Resistance, Neoplasm drug effects, Leukemia, Myeloid, Acute metabolism, Neoplastic Stem Cells drug effects, Pyrans pharmacology
- Abstract
Leukemia stem cells are known to exhibit multidrug resistance by expression of ATP-binding cassette (ABC) transporters which constitute transmembrane proteins capable of exporting a wide variety of chemotherapeutic drugs from the cytosol. We show here that human promyeloblastic leukemia KG-1a cells exposed to the histone deacetylase inhibitor phenylbutyrate resemble many characteristics of leukemia stem cells, including expression of functional ABC transporters such as P-glycoprotein, BCRP and MRP8. Consequently, KG-1a cells display resistance to the induction of apoptosis by various chemotherapeutic drugs. Resistance to apoptosis induction by chemotherapeutic drugs can be reversed by cyclosporine A, which effectively inhibits the activity of P-glycoprotein and BCRP, thus demonstrating ABC transporter-mediated drug resistance in KG-1a cells. However, KG-1a are highly sensitive to apoptosis induction by salinomycin, a polyether ionophore antibiotic that has recently been shown to kill human breast cancer stem cell-like cells and to induce apoptosis in human cancer cells displaying multiple mechanisms of drug and apoptosis resistance. Whereas KG-1a cells can be adapted to proliferate in the presence of apoptosis-inducing concentrations of bortezomib and doxorubicin, salinomycin does not permit long-term adaptation of the cells to apoptosis-inducing concentrations. Thus, salinomycin should be regarded as a novel and effective agent for the elimination of leukemia stem cells and other tumor cells exhibiting ABC transporter-mediated multidrug resistance., (2010 Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
18. Birth order and outcome after HLA-identical sibling donor transplantation.
- Author
-
Gratwohl A, Doehler B, Stern M, Bucher C, Passweg J, and Opelz G
- Subjects
- Anemia, Aplastic immunology, Anemia, Aplastic surgery, Graft Survival immunology, Histocompatibility Testing, Humans, Tissue Donors, Transplantation Immunology, HLA Antigens immunology, Hematopoietic Stem Cell Transplantation methods, Kidney Transplantation methods, Siblings
- Published
- 2009
- Full Text
- View/download PDF
19. Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells.
- Author
-
Fuchs D, Heinold A, Opelz G, Daniel V, and Naujokat C
- Subjects
- ATP Binding Cassette Transporter, Subfamily B, Member 1 biosynthesis, Animals, Cell Line, Tumor, Drug Resistance, Neoplasm, Humans, Mice, Proteasome Endopeptidase Complex biosynthesis, Proto-Oncogene Proteins c-bcl-2 biosynthesis, Antibiotics, Antineoplastic pharmacology, Apoptosis, Neoplasms metabolism, Pyrans pharmacology
- Abstract
Salinomycin is a polyether antibiotic isolated from Streptomyces albus that acts in different biological membranes as a ionophore with a preference for potassium. It is widely used as an anticoccidial drug in poultry and is fed to ruminants to improve nutrient absorption and feed efficiency. Salinomycin has recently been shown to selectively deplete human breast cancer stem cells from tumorspheres and to inhibit breast cancer growth and metastasis in mice. We show here that salinomycin induces massive apoptosis in human cancer cells of different origin, but not in normal cells such as human T lymphocytes. Moreover, salinomycin is able to induce apoptosis in cancer cells that exhibit resistance to apoptosis and anticancer agents by overexpression of Bcl-2, P-glycoprotein or 26S proteasomes with enhanced proteolytic activity. Salinomycin activates a distinct apoptotic pathway that is not accompanied by cell cycle arrest and that is independent of tumor suppressor protein p53, caspase activation, the CD95/CD95L system and the proteasome. Thus, salinomycin should be considered as a novel and effective anticancer agent that overcomes multiple mechanisms of apoptosis resistance in human cancer cells.
- Published
- 2009
- Full Text
- View/download PDF
20. Reassessing the impact of donor HLA-C genotype on long-term liver transplant survival.
- Author
-
Tran TH, Middleton D, Döhler B, Scherer S, Meenagh A, Sleator C, and Opelz G
- Subjects
- Adult, Alleles, Cohort Studies, Female, Genotype, Germany, Heterozygote, Homozygote, Humans, Killer Cells, Natural immunology, Male, Middle Aged, Receptors, KIR metabolism, Survival Analysis, Time Factors, Young Adult, Graft Survival genetics, Graft Survival immunology, HLA-C Antigens genetics, Liver Transplantation immunology, Tissue Donors
- Abstract
HLA-C is the major inhibitory ligand for killer immunoglobulin-like receptors (KIRs) that are expressed on natural killer (NK) cells. Based on their KIR specificity, HLA-C alleles can be divided into two groups, termed HLA-C1 and HLA-C2. Donor HLA-C group has recently been identified by Hanvesakul et al. (Am J Transplant 2008) as a critical determinant of clinical outcome following liver transplantation: Possession of at least one HLA-C group 2 allele by the donor was associated with significantly improved long-term graft and patient survival, presumably due to an inhibition of host NK cell function. To verify this study, we performed genotyping of 913 deceased liver donors for the relevant KIR epitopes of HLA-C and correlated the presence or absence of donor HLA-C2 genotype with graft and patient survival. In our study, donor HLA-C2 genotype had no impact on 10-year graft or patient survival. We cannot confirm a major role of donor HLA-C2 genotype on long-term allograft survival after liver transplantation.
- Published
- 2009
- Full Text
- View/download PDF
21. HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway.
- Author
-
Fuchs D, Berges C, Opelz G, Daniel V, and Naujokat C
- Subjects
- Antineoplastic Agents pharmacology, Boronic Acids pharmacology, Bortezomib, Cell Division drug effects, Cell Line, Cell Membrane drug effects, Cell Membrane enzymology, Cell Proliferation drug effects, Cell Survival drug effects, Cyclin-Dependent Kinase Inhibitor p21 metabolism, Drug Resistance, Neoplasm drug effects, G2 Phase drug effects, Humans, Myeloid Cell Leukemia Sequence 1 Protein, Proto-Oncogene Proteins c-bcl-2 metabolism, Pyrazines pharmacology, rhoA GTP-Binding Protein metabolism, Apoptosis drug effects, Burkitt Lymphoma metabolism, Hydroxymethylglutaryl-CoA Reductase Inhibitors pharmacology, Polyisoprenyl Phosphates metabolism, Simvastatin pharmacology
- Abstract
Simvastatin is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway required for the biosynthesis of cholesterol and higher isoprenoids such as geranylgeranyl pyrophosphate (GGPP). Apart from its capacity to lower cholesterol plasma levels and to protect against cardiovascular disease, simvastatin induces apoptosis in various cancer cells. We have generated human Namalwa Burkitt lymphoma cells that display general apoptosis resistance and hyperproliferation due to increased expression and proteolytic activity of 26S proteasomes in response to continuous treatment of the cells with the proteasome inhibitor bortezomib. In these cells, simvastatin does not inhibit proteasome activity, but induces apoptosis, G2/M cell cycle arrest and accumulation of p21(Waf1/Cip1), and effectively inhibits hyperproliferation. These effects are reversed by the addition of GGPP. GGPP-dependent plasma membrane localization of the small GTPase RhoA that is required for RhoA-mediated oncogenic signaling is completely inhibited by simvastatin. Finally, bortezomib but not simvastatin induces accumulation and stabilization of the anti-apoptotic protein Mcl-1, which is known to confer resistance to apoptosis in cancer cells. Thus, simvastatin overcomes bortezomib-induced apoptosis resistance by inhibiting synthesis of GGPP and disrupting a GGPP-dependent survival pathway.
- Published
- 2008
- Full Text
- View/download PDF
22. Comparison of histidine-tryptophan-ketoglutarate and University of Wisconsin preservation in renal transplantation.
- Author
-
Opelz G and Döhler B
- Subjects
- Adenosine, Allopurinol, Glucose, Glutathione, Humans, Insulin, Mannitol, Potassium Chloride, Procaine, Raffinose, Kidney Transplantation methods, Organ Preservation methods, Organ Preservation Solutions
- Published
- 2008
- Full Text
- View/download PDF
23. H-Y as a minor histocompatibility antigen in kidney transplantation: a retrospective cohort study.
- Author
-
Gratwohl A, Döhler B, Stern M, and Opelz G
- Subjects
- Adult, Animals, Cohort Studies, Female, Humans, Kidney Transplantation statistics & numerical data, Male, Mice, Multicenter Studies as Topic, Retrospective Studies, Sex Factors, Survival Rate, Graft Survival immunology, H-Y Antigen immunology, Kidney Transplantation immunology
- Abstract
Background: In haematopoietic stem-cell transplantation, male recipients of female grafts have an increased risk of graft-versus-host disease and female recipients have both an increased risk of rejection of male grafts and of specific T-cell and antibody reactivity against H-Y encoded gene products. By contrast, in kidney transplantation, the role of H-Y as a minor histocompatibility antigen has been disputed. We aimed to investigate whether an immunological H-Y effect occurs in kidney transplantation., Methods: We did a retrospective cohort study between 1985 and 2004 in 195 516 recipients of allografts from deceased donors. We used multivariate statistical methods to compare graft survival and death-censored graft survival rates for female and male donor kidneys in female and male recipients at 1 and 10 years., Findings: Graft loss was more common with kidneys from female donors than with those from male donors (p<0.001) after both 1 and 10 years. Female recipients had a lower rate of graft failure between the end of the first year and the end of the tenth year (p<0.001). Compared with all other combinations of sex, transplantation of male donor kidneys into female recipients was associated with an increased risk of graft failure during the first year (hazard ratio [HR] 1.08, 95% CI 1.03-1.14, p=0.003; death censored HR 1.11, 1.04-1.19, p=0.003) and between 2 and 10 years (HR 1.06, 1.01-1.10, p=0.008; death censored HR 1.10, 1.05-1.16, p<0.001)., Interpretation: H-Y minor histocompatibility affects human kidney transplantation.
- Published
- 2008
- Full Text
- View/download PDF
24. Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells.
- Author
-
Lob S, Konigsrainer A, Schafer R, Rammensee HG, Opelz G, and Terness P
- Subjects
- Cytokines pharmacology, Dendritic Cells drug effects, Gene Expression Regulation, Enzymologic, Humans, Kinetics, RNA, Small Interfering genetics, Stereoisomerism, Transfection, Tryptophan pharmacology, Dendritic Cells enzymology, Indoleamine-Pyrrole 2,3,-Dioxygenase genetics, Indoleamine-Pyrrole 2,3,-Dioxygenase metabolism, Tryptophan analogs & derivatives
- Abstract
Clinical trials have been started with the aim of inducing tumor immunity by blocking the immunosuppressive action of indoleamine-2,3-dioxygenase (IDO) with the IDO2-inhibitor dextro-1-methyl-tryptophan (D-1MT). Here we show that human dendritic cells (DCs) express both IDO-1 and IDO-2, but that only IDO1 mediates tryptophan catabolism; furthermore, its activity is blocked by levo-1MT, whereas D-1MT is inefficient. Consequently, in humans any possible antitumor effects of D-1MT cannot be attributed to abrogation of IDO activity in DCs as described in this study.
- Published
- 2008
- Full Text
- View/download PDF
25. Role of minor histocompatibility antigens in renal transplantation.
- Author
-
Heinold A, Opelz G, Scherer S, Ruhenstroth A, Laux G, Doehler B, and Tran TH
- Subjects
- Gene Frequency, Graft Survival genetics, Graft Survival immunology, Graft vs Host Disease genetics, Graft vs Host Disease immunology, HLA Antigens genetics, HLA Antigens immunology, Histocompatibility Testing, Humans, Immunophenotyping, Minor Histocompatibility Antigens genetics, Minor Histocompatibility Antigens immunology, Retrospective Studies, Kidney Transplantation immunology, Minor Histocompatibility Antigens physiology
- Abstract
In hematopoietic stem cell transplantation (HSCT), disparities between recipients and donors for minor histocompatibility antigens (mHags) have been shown to be related to graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) effects. We investigated the effect of mHag mismatches on kidney allograft survival. Out of 33 785 kidney transplants on which DNA and clinical data were available to the Collaborative Transplant Study (CTS), 702 recipient/donor pairs could be identified as HLA-A, -B and -DRB1 matched first transplants of Caucasian origin. These pairs were typed for genetic polymorphisms of the mHags HA-1, HA-2, HA-3, HA-8, HB-1, ACC-1 and UGT2B17. Because mHags are presented in an HLA-restricted manner, only HLA-A*02 positive pairs were included in the analysis of HA-1, HA-2 and HA-8. Similarly, only HLA-A*01, HLA-B*44 and HLA-A*24 positive pairs were considered for the evaluation of HA-3, HB-1 and ACC-1, respectively, whereas UGT2B17 compatible transplants were assessed in HLA-A*29 and HLA-B*44 positive pairs. None of the mHag disparities showed a statistically significant effect on death-censored 5-year graft survival. This report represents the first large-scale study on the relevance of mHags in kidney transplantation.
- Published
- 2008
- Full Text
- View/download PDF
26. Options for immunologic support of renal transplantation through the HLA and immunology laboratories.
- Author
-
Süsal C and Opelz G
- Subjects
- Graft Rejection prevention & control, Graft Survival drug effects, Graft Survival immunology, HLA Antigens genetics, Histocompatibility Testing, Humans, Polymorphism, Genetic, Transplantation, Homologous immunology, HLA Antigens immunology, Immunosuppressive Agents therapeutic use, Kidney Transplantation immunology
- Abstract
HLA and immunology laboratories are an integral part of clinical kidney transplant programs. They assist transplant clinicians with evaluating the immunological suitability of potential recipients for transplantation and selecting donor-recipient combinations with a low risk of immunological failure. With sophisticated new techniques becoming available for posttransplant immunological monitoring, laboratories play an increasing supporting role during posttransplant follow up. The level of precision at which immunological testing predicts clinical outcome, however, leaves room for improvement. In this article, we summarize the current state of diagnostics, discuss problems, and point out promising developments.
- Published
- 2007
- Full Text
- View/download PDF
27. Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens.
- Author
-
Weimer R, Süsal C, Yildiz S, Staak A, Pelzl S, Renner F, Dietrich H, Daniel V, Kamali-Ernst S, Ernst W, Padberg W, and Opelz G
- Subjects
- Adult, Antibodies immunology, Biomarkers, Chronic Disease, Complement C4 metabolism, Female, Graft Rejection immunology, Graft Rejection prevention & control, Histocompatibility Antigens Class I immunology, Histocompatibility Antigens Class II immunology, Humans, Ki-1 Antigen blood, Ki-1 Antigen immunology, Kidney Diseases metabolism, Kidney Diseases pathology, Male, Middle Aged, Prognosis, Solubility, Th2 Cells immunology, Transplantation, Homologous immunology, Treatment Outcome, Immunosuppressive Agents pharmacology, Ki-1 Antigen analysis, Kidney Diseases immunology, Kidney Transplantation immunology, Kidney Transplantation pathology, Neopterin immunology
- Abstract
Immunological monitoring for chronic allograft nephropathy (CAN) is of great potential interest. We assessed serum soluble CD30 (sCD30) together with in vitro Th2-type responses (IL-4, IL-10, CD4 helper activity) and neopterin in a prospective study of 84 renal transplant recipients with 2-year follow-up. Patients were randomized to CsA/Aza, CsA/MMF and Tacr/Aza, respectively, to analyze the effect of immunosuppression on posttransplant sCD30 and neopterin. ATG induction and acute rejections did not alter sCD30 levels whereas CMV disease was associated with transient upregulation of sCD30 (p = 0.003 at 4 months) and sustained upregulation of neopterin (corrected for graft function (Neo/CR) p = 0.005 at 2 years). Tacr versus CsA treatment proved to be an independent variable associated with downregulation of 1-year sCD30, which was positively related to Neo/CR (p = 0.007 and 0.01, respectively; logistic regression). Importantly, increased 1-year sCD30 and Neo/CR were associated with decreased glomerular filtration rate at 2 years (p = 0.02 and p < 0.0005, respectively) and evidence of CAN (p < 0.0005). High 1-year sCD30 could not be attributed to enhanced Th2-type responses and was not associated with HLA antibody formation. Our data suggest that elevated sCD30 and neopterin predict graft deterioration by CAN. Tacr effectively downregulates these responses and might be of advantage in patients with elevated sCD30 or neopterin.
- Published
- 2006
- Full Text
- View/download PDF
28. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil.
- Author
-
Robson R, Cecka JM, Opelz G, Budde M, and Sacks S
- Subjects
- Adult, Cohort Studies, Female, Graft Survival, Humans, Incidence, Male, Middle Aged, Mycophenolic Acid therapeutic use, Prospective Studies, Risk Factors, Graft Rejection drug therapy, Graft Rejection epidemiology, Immunosuppressive Agents therapeutic use, Kidney Transplantation statistics & numerical data, Lymphoma epidemiology, Mycophenolic Acid analogs & derivatives, Registries statistics & numerical data
- Abstract
This large prospectively conducted observational cohort study examined the risk of lymphoma and other malignancies with mycophenolate mofetil (MMF) in de novo renal transplant recipients. A total of 6751 patients receiving MMF, and an equal number of matched controls receiving non-MMF-based immunosuppression, were identified from two large registries (Organ Procurement and Transplantation Network/United Network for Organ Sharing (OPTN/UNOS) and Collaborative Transplant Study (CTS)) and followed for 3 years. The primary endpoint was development of lymphoma. Secondary endpoints included development of any malignancy. There was no evidence of any increased risk of developing lymphoma or malignancy with MMF. The risk of developing lymphoma with MMF compared with the non-MMF cohort was not higher in either the CTS registry (relative risk (95% confidence interval); 0.4 (0.17-0.94)) or the OPTN/UNOS registry (1.04 (0.61-1.78)). In the MMF group, there was a trend toward a lower risk of malignancy in both registries (OPTN/UNOS 0.86 (0.69-1.07); CTS 0.79 (0.61-1.02)) and a significant increase in time to malignancy in the CTS dataset (p < 0.026). This study has demonstrated that MMF is not associated with an increased risk of lymphoma or other malignancies post-renal transplant, and may even be associated with a lower risk in some populations.
- Published
- 2005
- Full Text
- View/download PDF
29. A positive crossmatch and treatment with IvIg.
- Author
-
Opelz G and Süsal C
- Subjects
- Humans, HLA Antigens immunology, Histocompatibility Testing, Immunoglobulins, Intravenous therapeutic use, Immunosuppressive Agents therapeutic use, Transplantation Immunology
- Published
- 2005
- Full Text
- View/download PDF
30. Improved long-term outcomes after renal transplantation associated with blood pressure control.
- Author
-
Opelz G and Döhler B
- Subjects
- Adult, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Antihypertensive Agents therapeutic use, Creatinine blood, Female, Follow-Up Studies, Graft Rejection epidemiology, Histocompatibility Testing, Humans, Immunosuppressive Agents therapeutic use, Kidney Transplantation immunology, Male, Middle Aged, Postoperative Complications epidemiology, Postoperative Complications physiopathology, Time Factors, Treatment Outcome, Blood Pressure physiology, Hypertension epidemiology, Kidney Transplantation physiology
- Abstract
Hypertension has a negative impact on long-term outcomes after renal transplantation. We investigated the effect of a recent decline in blood pressure among renal transplant patients in the Collaborative Transplant Study (CTS) database on long-term graft and patient survival. CTS data were used to evaluate transplant outcomes in relation to recipient systolic blood pressure (SBP) for 24,404 first cadaver kidney recipients transplanted between 1987 and 2000. Patients whose SBP was > 140 mmHg at 1 year posttransplantation but controlled to < or = 140 mmHg by 3 years had significantly improved long-term graft outcome compared with patients with sustained high SBP to 3 years (RR 0.79; CI 0.73-0.86; p < 0.001). Additional examination at 5 years showed that SBP lowering after year 3 was associated with improved 10-year graft survival (RR 0.83; CI 0.72-0.96; p = 0.01), whereas even a temporary increase in SBP at 3 years was associated with worse survival (RR 1.37; CI 1.19-1.58; p < 0.001). Changes in SBP were paralleled by changes in the incidence of cardiovascular death among recipients younger than 50 but not in older recipients. Lowering SBP, even after several years of posttransplantation hypertension, is associated with improved graft and patient survival in renal allograft recipients.
- Published
- 2005
- Full Text
- View/download PDF
31. A cell line model for the differentiation of human dendritic cells.
- Author
-
Berges C, Naujokat C, Tinapp S, Wieczorek H, Höh A, Sadeghi M, Opelz G, and Daniel V
- Subjects
- Antigens, CD34 immunology, Cell Line, Culture Media, Serum-Free, Dendritic Cells immunology, Flow Cytometry, Humans, Lipopolysaccharide Receptors immunology, Polymerase Chain Reaction, Reproducibility of Results, Dendritic Cells cytology, Models, Biological
- Abstract
We have identified human monocytic (THP-1) and myelogenous CD34+ (KG-1) leukemia cell lines that can be differentiated rapidly into mature dendritic cells (DCs) when cultured in serum-free medium containing GM-CSF, TNF-alpha, and ionomycin. These hematopoietic cell line-derived DCs are highly pure and monotypic, and display the morphologic, phenotypic, molecular, and functional properties of DCs generated from human donor-derived monocytes or CD34+ hematopoietic progenitor cells. During differentiation into mature DCs, the cells exhibit de novo cell-surface expression of CD83, CD80, CD86, CD40, CD206, CD209, CD120a, CD120b, and intracellular synthesis of IL-10, increase their endocytotic capacity, and acquire characteristic stellate morphology. To further define the cells as DCs, cytosolic induction and upregulation of RelB and RelA (p65), transcription factors of the NF-kappaB/Rel family essential for differentiation and maturation of DCs, as well as upregulation of the immunoproteasome subunits LMP2, LMP7, and MECL-1, and the proteasome activator PA28alpha, components essential for efficient MHC class I peptide antigen processing, were demonstrated during differentiation of the cells. In contrast to the cell lines, the cell line-derived mature DCs are capable of stimulating allogeneic CD4+ and CD8+ T cells, ultimately defining them as potent antigen-presenting cells. The approach to differentiate THP-1 and KG-1 cells into immature and mature DCs may serve as an experimental model to study molecular events and pathways that govern the differentiation of human malignant myeloid precursors, monocytes, and CD34+ hematopoietic progenitor cells into DCs.
- Published
- 2005
- Full Text
- View/download PDF
32. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies.
- Author
-
Opelz G
- Subjects
- Chronic Disease, Cytotoxicity Tests, Immunologic, Graft Survival immunology, Humans, Subacute Sclerosing Panencephalitis, Antilymphocyte Serum immunology, Graft Rejection immunology, HLA Antigens immunology, Histocompatibility Testing, Isoantibodies analysis, Kidney Transplantation immunology, Living Donors
- Abstract
Background: The presence of panel-reactive antibodies (PRA) against HLA antigens before transplantation is associated with early rejection of kidney grafts from cadaver donors. Transplants from HLA-identical sibling donors do not provide a target for antibodies to HLA antigens and should therefore not be affected by PRA., Methods: Data from the Collaborative Transplant Study were used to examine the influence of PRA on graft survival. Uncensored graft survival and death-censored graft survival were calculated, and the data were analysed by multivariate Cox's regression methods., Findings: Among recipients of HLA-identical sibling transplants, 3001 patients with no PRA had significantly higher 10-year graft survival (72.4% [SE 1.1]) than 803 patients with 1-50% PRA (63.3% [2.5]; p=0.0006) or 244 patients with more than 50% PRA (55.5% [4.0]; p<0.0001). The effect of PRA became apparent after the first post-transplant year and was, therefore, strikingly different from the early steep decline in graft survival during the first year associated with PRA in recipients of cadaver kidneys. We could not discern whether graft loss was a direct effect of non-HLA humoral sensitisation or whether PRA served as an indicator of heightened immunity against non-HLA transplantation antigens., Interpretation: PRA reactivity is strongly associated with long-term graft loss in kidney transplants from HLA-identical sibling donors., Relevance to Practice: Our findings suggest that non-HLA immunity has a much stronger role in clinical transplantation than previously thought. In contrast to immunity against HLA mediated by antibodies present before transplantation, which leads to early acute graft rejection, non-HLA immunity is associated with chronic graft loss. The possibility of identifying recipients at increased risk of late graft loss before transplantation could be used to devise specific immunosuppressive strategies for these patients.
- Published
- 2005
- Full Text
- View/download PDF
33. Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients.
- Author
-
Opelz G, Döhler B, and Laux G
- Subjects
- Adult, Female, Graft Rejection, Humans, Male, Middle Aged, Prospective Studies, Survival Analysis, Time Factors, Adrenal Cortex Hormones pharmacology, Graft Survival drug effects, Heart Transplantation, Kidney Transplantation, Withholding Treatment
- Abstract
A large prospective study of steroid withdrawal was performed within the framework of the Collaborative Transplant Study to analyze long-term graft and patient outcome in renal and heart transplant recipients. Steroids were withdrawn no earlier than 6 months posttransplantation. A comparison of 7-year outcomes in renal transplant recipients (94% receiving cyclosporine; 97% Caucasian) showed a benefit of steroid withdrawal versus steroid continuation in retrospectively matched controls, for graft survival (81.9% +/- 1.8% vs. 75.3% +/- 1.2%, p = 0.0001), patient survival (88.8% +/- 1.5% vs. 84.3 +/- 1.0%; p = 0.0016) and death-censored graft survival (91.8% +/- 1.3% vs. 87.9%+/- 1.0%: p = 0.0091). Steroid withdrawal was associated with improved graft survival in heart recipients also (76.2% +/- 2.4% vs. 66.9% +/- 1.7%, p = 0.0008). A total of 58.6% of renal recipients and 44.3% of heart recipients never required steroids during follow up. Rates of acute rejection and renal dysfunction did not differ between steroid-free and steroid-continuation groups. Steroid withdrawal was associated with significantly improved cardiovascular risk factors compared with steroid continuation. Rates of the development of osteoporosis and cataracts did not differ in the entire patient cohort, but were strikingly lower in patients taken off steroids during the first posttransplant year.
- Published
- 2005
- Full Text
- View/download PDF
34. Evaluation of T-cell receptor repertoires in patients with long-term renal allograft survival.
- Author
-
Alvarez CM, Opelz G, Giraldo MC, Pelzl S, Renner F, Weimer R, Schmidt J, Arbeláez M, García LF, and Süsal C
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Complementarity Determining Regions chemistry, Complementarity Determining Regions genetics, Female, Humans, Male, Middle Aged, Receptors, Antigen, T-Cell chemistry, Receptors, Antigen, T-Cell genetics, Renal Dialysis, Time Factors, Transplantation, Homologous, Complementarity Determining Regions immunology, Graft Survival immunology, Kidney Transplantation, Receptors, Antigen, T-Cell immunology
- Abstract
The mechanisms underlying long-term acceptance of kidney allografts in humans under minimal or no maintenance immunosuppression are poorly understood. We analyzed the T-cell receptor (TCR) repertoires in circulating T cells of patients with long-term (> or = 9 years) renal allograft survival with (LTS-IS) and without immunosuppression (LTS-NoIS). T cells of LTS patients exhibited strongly altered TCR Vss usage, including an increased frequency of oligoclonality and a decreased frequency of polyclonality. All 3 LTS-NoIS and 12 of 16 LTS-IS patients demonstrated oligoclonality in at least three or more TCR V beta families, and the frequency of oligoclonality in these patients was significantly higher as compared to patients with well-functioning grafts at 3 years (p < 0.005 both), an uncomplicated course during the first year (p < 0.0001, both), acute rejection (p < 0.0001, both), chronic allograft nephropathy at 7 (p < 0.0001, both) or 13 years (p < 0.0001, both), dialysis patients (p < 0.0001, both) or healthy controls (p < 0.0001, both). In contrast to LTS patients, all other studied patient groups exhibited a polyclonal TCR repertoire. Our data indicate that TCR alteration is a common feature of long-term allograft outcome, which might be explained by clonal deletion, exhaustion of alloreactive T cells or predominant expression of particular T-cell subpopulations, such as regulatory T cells.
- Published
- 2005
- Full Text
- View/download PDF
35. Regulation of human auto- and alloreactive T cells by indoleamine 2,3-dioxygenase (IDO)-producing dendritic cells: too much ado about IDO?
- Author
-
Terness P, Chuang JJ, Bauer T, Jiga L, and Opelz G
- Subjects
- Antineoplastic Agents pharmacology, Cells, Cultured, Dendritic Cells cytology, Dendritic Cells enzymology, Gene Expression Regulation, Enzymologic drug effects, Humans, Immune Tolerance drug effects, Immune Tolerance immunology, Indoleamine-Pyrrole 2,3,-Dioxygenase biosynthesis, Interferon-gamma pharmacology, Interleukin-3 Receptor alpha Subunit, Isoantigens immunology, Monocytes cytology, Monocytes enzymology, Monocytes immunology, Multiple Sclerosis enzymology, Multiple Sclerosis immunology, Muromonab-CD3 immunology, Receptors, CCR6, Receptors, Chemokine biosynthesis, Receptors, Chemokine immunology, Receptors, Interleukin-3 biosynthesis, Receptors, Interleukin-3 immunology, T-Lymphocytes cytology, Transcription, Genetic immunology, Dendritic Cells immunology, Gene Expression Regulation, Enzymologic immunology, Indoleamine-Pyrrole 2,3,-Dioxygenase immunology, Lymphocyte Activation immunology, Myelin Basic Protein immunology, T-Lymphocytes immunology
- Abstract
Although dendritic cells (DCs) strongly stimulate the immune response, they can also induce unresponsiveness. Recently, a human monocyte-derived DC subpopulation was described that constitutively expresses indoleamine 2,3-dioxygenase (IDO). These DCs were defined as nonadherent CD123+/CC chemokine receptor 6+ (CCR6+) cells that suppress the allogeneic T-cell response. In the present study, we generated nonadherent, mature DCs from human blood monocytes. As expected, in addition to the classic markers, these cells expressed CD123 and CCR6. Reverse transcription-polymerase chain reaction (RT-PCR), however, did not show IDO gene transcription, nor did we detect enzymatic IDO activity. Treating the cells with interferon-gamma (IFN-gamma) resulted in significant IDO production. Subsequently, we studied the regulatory properties of IDO-producing DCs on autologous and allogeneic T-cell responses. Neither OKT3-stimulated T cells of healthy donors nor myelin basic protein (MBP)-specific T cells of patients with multiple sclerosis (MS) were suppressed by autologous IDO DCs. However, whereas IDO(neg) DCs supported further stimulation of preactivated MBP-specific T cells of an MS patient, IDO(pos) DCs had lost this capacity. The allogeneic T-cell response was only marginally suppressed by IDO DCs. Our findings show that nonadherent CD123+/CCR6+ human DCs do not constitutively express IDO, and, even if they express the enzyme after IFN-gamma treatment, they possess only limited T-cell regulatory function.
- Published
- 2005
- Full Text
- View/download PDF
36. Relevance of IL10, TGFbeta1, TNFalpha, and IL4Ralpha gene polymorphisms in kidney transplantation: a collaborative transplant study report.
- Author
-
Mytilineos J, Laux G, and Opelz G
- Subjects
- Cadaver, Humans, Interleukin-10 metabolism, Polymorphism, Single Nucleotide, Promoter Regions, Genetic, Receptors, Interleukin-4 metabolism, Time Factors, Transforming Growth Factor beta metabolism, Transforming Growth Factor beta1, Tumor Necrosis Factor-alpha metabolism, Graft Survival genetics, Interleukin-10 genetics, Kidney metabolism, Receptors, Interleukin-4 genetics, Transforming Growth Factor beta genetics, Transplants, Tumor Necrosis Factor-alpha genetics
- Abstract
Single nucleotide polymorphisms (SNPs) of cytokine genes have been shown to influence cytokine plasma levels. Cytokines are important mediators during organ graft rejection. It was reported that certain cytokine genotypes are associated with improved kidney graft survival. In the present study, SNPs within the IL10 promoter gene, the first exon of the TGFbeta1 gene, the TNFalpha promoter gene, and the IL4Ralpha gene were analyzed in 2298 first and 1901 repeat cadaver kidney recipients. We found no significant effect on the survival rate of first grafts. Among retransplants, we observed that recipients who were homozygous for the high TNFalpha producer genotype -308 A had a significantly lower graft survival rate than patients who were carriers of the low producer genotype -308 G (at 3 years: 63.0% vs. 79.5%; pcorrected = 0.0116). The results of this large-scale study suggest that IL10, TGFbeta1, TNFalpha, and IL4Ralpha cytokine genotypes do not affect the survival of primary kidney grafts. The outcome of retransplants appears to be affected by TNFalpha genotypes only.
- Published
- 2004
- Full Text
- View/download PDF
37. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation.
- Author
-
Offman J, Opelz G, Doehler B, Cummins D, Halil O, Banner NR, Burke MM, Sullivan D, Macpherson P, and Karran P
- Subjects
- Acute Disease, Azathioprine adverse effects, Bone Marrow pathology, Follow-Up Studies, Heart Transplantation pathology, Humans, Immunosuppression Therapy adverse effects, Immunosuppressive Agents adverse effects, Kidney Transplantation pathology, Leukemia, Myeloid mortality, Leukemia, Myeloid pathology, Lung Transplantation pathology, Myelodysplastic Syndromes mortality, Myelodysplastic Syndromes pathology, Retrospective Studies, Survival Analysis, Time Factors, Base Pair Mismatch genetics, DNA Repair genetics, Heart Transplantation adverse effects, Kidney Transplantation adverse effects, Leukemia, Myeloid epidemiology, Leukemia, Myeloid genetics, Lung Transplantation adverse effects, Myelodysplastic Syndromes epidemiology, Myelodysplastic Syndromes genetics
- Abstract
Immunosuppression after organ transplantation is an acknowledged risk factor for skin cancer and lymphoma. We examined whether there was also an excess of leukemia in patients after transplantation and whether this might be related to a particular immunosuppressive treatment. Data from more than 170 000 patients indicated that organ transplantation is associated with a significantly increased risk for acute myeloid leukemia (AML). AML was more frequent after heart transplantation and lung transplantation than after kidney transplantation and was associated with immunosuppression by azathioprine, a thiopurine prodrug. Cellular resistance to thiopurines is associated with DNA mismatch repair (MMR) deficiency. We demonstrate that thiopurine treatment of human cells in vitro selects variants with defective MMR. Consistent with a similar selection in patient bone marrow, in 7 of 7 patients, transplant-related AML/myelodysplastic syndrome (MDS) exhibited the microsatellite instability (MSI) that is diagnostic for defective MMR. Because MSI occurs infrequently in de novo AML, we conclude that the selective proliferation of MMR-defective, azathioprine-resistant myeloid cells may contribute significantly to the development of AML/MDS in patients who have received organ transplants. Identifying azathioprine as a risk factor for AML/MDS suggests that discontinuing the use of azathioprine as an immunosuppressant might reduce the incidence of posttransplantation AML/MDS.
- Published
- 2004
- Full Text
- View/download PDF
38. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report.
- Author
-
Opelz G, Döhler B, and Ruhenstroth A
- Subjects
- Adolescent, Adult, Antibodies, Monoclonal therapeutic use, Antigens, Viral blood, Child, Child, Preschool, Cytomegalovirus immunology, Female, Graft Rejection microbiology, Humans, Immunosuppressive Agents therapeutic use, Infant, Infant, Newborn, Male, Middle Aged, Mycophenolic Acid therapeutic use, Survival Rate, Antilymphocyte Serum therapeutic use, Antiviral Agents therapeutic use, Cytomegalovirus Infections prevention & control, Graft Survival, Mycophenolic Acid analogs & derivatives, Organ Transplantation
- Abstract
We investigated relationships between cytomegalovirus (CMV) seropairing and CMV prophylaxis on graft outcome in recipients of solid organ transplants. Transplants carried out from 1985 to 2002 and reported to the Collaborative Transplant Study were analyzed. In cadaver kidney recipients, CMV prophylaxis was significantly associated with improved graft survival only in the seronegative-recipient/seropositive-donor combination (at 3 years: 79.4% with prophylaxis vs. 73.5% without prophylaxis; RR 0.80, p < 0.0001). Among patients who had a functioning graft at 1 year, significantly fewer patients who received CMV prophylaxis received rejection treatment in the preceding year (26.3%), compared with patients who did not receive prophylaxis (32.4%) (p = 0.0001), suggesting an inhibitory effect of CMV prophylaxis on acute rejection. Significant improvements in graft survival after CMV prophylaxis were found also in CMV-negative recipients of CMV-positive heart, and lung or heart-lung transplants, but not liver transplants. The age of the recipient had a differential effect on graft and patient survival after CMV prophylaxis. Use of antilymphocyte antibodies or mycophenolate mofetil was not associated with an enhanced CMV effect on graft outcome. These results may contribute to a better understanding of the influence of pretransplant CMV serology on the effect of CMV prophylaxis.
- Published
- 2004
- Full Text
- View/download PDF
39. Lymphomas after solid organ transplantation: a collaborative transplant study report.
- Author
-
Opelz G and Döhler B
- Subjects
- Adolescent, Adult, Child, Heart Transplantation adverse effects, Heart Transplantation mortality, Heart-Lung Transplantation adverse effects, Heart-Lung Transplantation mortality, Humans, Immunosuppression Therapy adverse effects, Incidence, Kidney Transplantation adverse effects, Kidney Transplantation mortality, Liver Transplantation adverse effects, Liver Transplantation mortality, Living Donors, Middle Aged, Survival Rate, Time Factors, Tissue Donors, Lymphoma epidemiology, Lymphoma, Non-Hodgkin epidemiology, Transplantation adverse effects
- Abstract
We used the Collaborative Transplant Study database to analyze the incidence, risk, and impact of malignant lymphomas in approximately 200,000 organ transplant recipients. Over a 10-year period, the risk in renal transplant recipients was 11.8-fold higher than that in a matched nontransplanted population (p<0.0001). The majority of lymphomas were diagnosed after the first post-transplant year. Heart-lung transplants showed the highest relative risk (RR 239.5) among different types of organ transplants. In kidney recipients, immunosuppression with cyclosporine did not confer added risk compared with azathioprine/steroid treatment, whereas treatment with FK506 increased the risk approximately twofold. Induction therapy with OKT3 or ATG, but not with anti-IL2 receptor antibodies, increased the risk of lymphoma during the first year. Antirejection therapy with OKT3 or ATG also increased the risk. First-year mortality in renal and heart transplant patients with lymphoma was approximately 40% and 50%, respectively, and showed no improvement in recent years. A pattern of preferential localization to the vicinity of the transplant was noted, and the prognosis of the patient was related to localization. This study highlights the continuing risk for lymphoma with time post-transplantation, the contribution of immunosuppression to increased risk, and continuing poor outcomes in patients with post-transplant lymphoma.
- Published
- 2004
- Full Text
- View/download PDF
40. Cell cycle- and activation-dependent regulation of cyclosporin A-induced T cell apoptosis.
- Author
-
Naujokat C, Daniel V, Bauer TM, Sadeghi M, and Opelz G
- Subjects
- Acetylcysteine pharmacology, Cell Cycle, Cysteine Endopeptidases, Cysteine Proteinase Inhibitors pharmacology, Humans, Jurkat Cells, Multienzyme Complexes antagonists & inhibitors, Proteasome Endopeptidase Complex, T-Lymphocytes cytology, T-Lymphocytes drug effects, Acetylcysteine analogs & derivatives, Apoptosis, Cyclosporine pharmacology, Immunosuppressive Agents pharmacology, Lymphocyte Activation, T-Lymphocytes immunology
- Abstract
The immunosuppressive agent cyclosporin A (CsA), which interferes with signal transduction pathways leading to cytokine gene transcription in activated T cells, was investigated regarding its ability to induce apoptosis in T cells undergoing cell cycle progression and activation. In Jurkat and peripheral CD4+ T cells, CsA was found to markedly induce apoptosis at the G0 phase of the cell cycle. Susceptibility to CsA-induced apoptosis progressively decreased during cell cycle progression to the S and G2/M phase, and subsequent T cell receptor- and mitogen-mediated activation totally abrogated CsA-induced apoptosis. Because CsA is an inhibitor of the chymotryptic peptidase activity of the proteasome, susceptibility to apoptosis induced by the proteasome inhibitor lactacystin was investigated under the same conditions. A progressive increase of the susceptibility of T cells to lactacystin-induced apoptosis during cell cycle progression and activation was demonstrated. Intracellular protein levels of the cyclin-dependent kinase inhibitor p27(Kip1)decreased from the G0 to G2/M phase and from the cycling to the activation state, but remained unchanged during the induction of apoptosis by CsA and lactacystin, suggesting a role of p27(Kip1)in the regulation of susceptibility to apoptosis during cell cycle progression and activation. Inhibition of CsA- but not lactacytin-induced apoptosis by overexpression of Bcl-2 in Jurkat T cells revealed that CsA and proteasome inhibitors activate different apoptotic pathways, while both CsA- and lactacystin-induced apoptosis were found to be dependent on caspase activation and independent of the FasL/Fas system. The results show that T cells can progressively regulate their susceptibility to apoptosis during cell cycle progression and activation in a stimulus-dependent manner, and suggest that lactacystin, but not CsA, is able to deplete activated T cells by apoptosis, a mechanism deemed necessary for the induction of allograft tolerance.
- Published
- 2003
- Full Text
- View/download PDF
41. Serial peripheral blood perforin and granzyme B gene expression measurements for prediction of acute rejection in kidney graft recipients.
- Author
-
Simon T, Opelz G, Wiesel M, Ott RC, and Süsal C
- Subjects
- Biomarkers blood, Drug Therapy, Combination, Female, Graft Rejection blood, Granzymes, Histocompatibility Testing, Humans, Immunosuppressive Agents therapeutic use, Kidney Transplantation pathology, Male, Membrane Glycoproteins blood, Middle Aged, Perforin, Polymerase Chain Reaction, Pore Forming Cytotoxic Proteins, ROC Curve, Reference Values, Reoperation, Reproducibility of Results, Sensitivity and Specificity, Serine Endopeptidases blood, Time Factors, Graft Rejection diagnosis, Kidney Transplantation immunology, Membrane Glycoproteins genetics, Serine Endopeptidases genetics
- Abstract
In the present study we investigated whether peripheral blood gene expression measurements may serve as an early and non-invasive tool to predict renal allograft rejection. Peripheral blood was collected twice weekly after transplantation and gene expression was measured using real-time polymerase chain reaction (PCR). Recipients with acute rejection (n = 17) had higher levels of perforin and granzyme B transcript on days 5-7, 8-10, 11-13, 17-19, 20-22, and 26-29, as compared to patients without rejection (n = 50, p < 0.05 in all cases). Rejection diagnosis using gene expression criteria, determined with receiver operating characteristic (ROC) curves, was possible 2-30 days before traditional diagnosis (median 11 days). The best diagnostic result was obtained from samples taken on days 8-10, with a specificity of 90% and a sensitivity of 82% for perforin, and a specificity of 87% and sensitivity of 72% for granzyme B. Decreases in perforin (p < 0.01) and granzyme B expression (p < 0.05) were observed after initiation of anti-rejection therapy. Our data indicate that gene expression measurement is a useful tool for the recognition of graft rejection in its earliest stages. Serial measurements could be implemented as a monitoring system to highlight patients at higher risk of rejection, making them candidates for biopsy or pre-emptive anti-rejection therapy.
- Published
- 2003
- Full Text
- View/download PDF
42. Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma.
- Author
-
Neben K, Mytilineos J, Moehler TM, Preiss A, Kraemer A, Ho AD, Opelz G, and Goldschmidt H
- Subjects
- Adult, Aged, Aged, 80 and over, Case-Control Studies, Gene Frequency, Genotype, Haplotypes, Humans, Male, Middle Aged, Multiple Myeloma diagnosis, Multiple Myeloma mortality, Prognosis, Salvage Therapy, Survival Analysis, Multiple Myeloma genetics, Polymorphism, Single Nucleotide, Promoter Regions, Genetic genetics, Thalidomide therapeutic use, Tumor Necrosis Factor-alpha genetics
- Abstract
Thalidomide (Thal) is a drug with antiangiogenic, anti-inflammatory, and immunomodulatory properties that was found to inhibit the production of tumor necrosis factor-alpha (TNF-alpha) in vitro. We studied single nucleotide polymorphisms at positions -308 and -238 of the TNF-alpha gene promoter and measured the corresponding TNF-alpha cytokine levels in 81 patients (pts) with refractory and relapsed multiple myeloma (MM) who were treated with Thal. In myeloma pts carrying the TNF-238A allele (n = 8), we found a correlation with higher pretreatment TNF-alpha levels in peripheral blood (P =.047). After Thal administration, this TNF-238A group had a prolonged 12-month progression-free and overall survival of 86% and 100% versus 44% and 84% (P =.003 and P =.07) in pts with the TNF-238G allele, respectively. These findings suggest that regulatory polymorphisms of the TNF-alpha gene can affect TNF-alpha production and predict the outcome after Thal therapy, particularly in those MM pts who are genetically defined as "high producers" of TNF-alpha.
- Published
- 2002
43. Microchimerism in bone marrow-derived CD34(+) cells of patients after liver transplantation.
- Author
-
Nierhoff D, Horvath HC, Mytilineos J, Golling M, Bud O, Klar E, Opelz G, Voso MT, Ho AD, Haas R, and Hohaus S
- Subjects
- Adolescent, Adult, Bone Marrow Cells chemistry, Bone Marrow Cells immunology, DNA analysis, Female, Graft Survival, HLA-DR Antigens genetics, HLA-DRB1 Chains, Histocompatibility, Humans, Male, Middle Aged, Polymerase Chain Reaction, Tissue Donors, Antigens, CD34 analysis, Bone Marrow Cells cytology, Chimera, Liver Transplantation
- Abstract
Lymphoid and dendritic cells of donor origin can be detected in the recipient several years after a solid organ transplantation. This phenomenon is termed microchimerism and could play a role in the induction of tolerance. The fate of other hematopoietic cells transferred by liver transplantation, in particular of stem and progenitor cells, is unknown. For this reason, we studied peripheral blood and bone marrow samples of 12 patients who had received a liver transplant from an HLA-DR mismatched donor. Eight patients were long-term survivors between 2.8 and 10.1 years after allografting. CD34(+) cells from bone marrow were highly enriched with the use of a 2-step method, and a nested polymerase chain reaction was applied to detect donor cells on the basis of allelic differences of the HLA-DRB1 gene. Rigorous controls with DRB1 specificities equal to the donor and host were included. In 5 of 8 long-term liver recipients, donor-specific CD34(+) cells could be detected in bone marrow. Microchimerism in the CD34(+) cell fraction did not correlate to the chimeric status in peripheral blood. In conclusion, our results demonstrate a frequent microchimerism among bone marrow-derived CD34(+) cells after liver transplantation. The functional role of this phenomenon still needs to be defined. (Blood. 2000;96:763-767)
- Published
- 2000
44. Inverse association between IgG-anti-kappa and antierythrocyte autoantibodies in patients with cold agglutination.
- Author
-
Terness P, Navolan D, Opelz G, and Roelcke D
- Subjects
- Antibody Specificity, B-Lymphocytes immunology, Humans, Anemia, Hemolytic, Autoimmune immunology, Autoantibodies immunology, Erythrocytes immunology, Immunoglobulin G immunology, Immunoglobulin kappa-Chains immunology
- Abstract
It has been known for a long time that IgG-anti-F(ab')(2) antibodies (Abs) are able to suppress the B-cell response. We showed that natural IgG-anti-F(ab')(2) autoantibodies appear in the serum of patients with cold agglutination. If the anti-F(ab')2 Ab suppresses cold agglutinin (CA)-producing B cells, one would expect an inverse correlation between the titers of these two Abs. Our study confirmed this correlation. Subsequent experiments showed that some anti-F(ab')(2) Abs bind to the hinge region of IgG. It was difficult to explain how this Ab suppresses CA-producing B cells, which are of IgM isotype. Here we show that patients with cold agglutination have an IgG-anti-kappa light chain autoantibody in their serum. This is another member of the anti-F(ab')(2) Ab group. Because the vast majority of CAs are IgM-kappa Abs, the anti-kappa Ab might suppress CA-producing B cells. If this is the case, there should be an inverse association between the titer of anti-kappa Ab and CA. In a group of 302 patients, we found that high titers of the anti-kappa Ab correlate with low titers of CA and vice versa (P =.009). Interestingly, this association is found only in patients whose disease is caused by noninfectious agents, including mainly B-cell proliferations (P =.0058). Our data show that the inverse correlation is not confined to a particular CA autoantibody specificity. The results are discussed in the light of recent findings showing that anti-IgM Abs may either inactivate or kill tumoral B cells by apoptosis.
- Published
- 1999
45. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study.
- Author
-
Opelz G, Wujciak T, and Ritz E
- Subjects
- Graft Rejection, Humans, Blood Pressure, Graft Survival, Kidney Transplantation
- Abstract
Immunological rejection is the most important cause of kidney transplant failure. Recently, nonimmunological causes of long-term allograft failure have become more widely appreciated. In primary chronic renal disease, blood pressure is of overriding importance for long-term renal function. The role of blood pressure in determining long-term transplant outcome has not yet been established. We studied the influence of blood pressure post-transplantation on long-term kidney graft outcome in 29,751 patients. Outpatient blood pressure measurements were recorded and reported to the Collaborative Transplant Study. Graft and patient survival rates were analyzed over seven years in relation to blood pressure. Increased levels of systolic and diastolic blood pressure post-transplantation were associated with a graded increase of subsequent graft failure (P < 0.0001). Chronic graft failure was significantly associated with blood pressure even when patient death was censored (P < 0.0001). Cox regression analysis established increased blood pressure as an independent risk factor for graft failure. We conclude that post-transplant blood pressure is a highly significant predictor of long-term kidney graft outcome. Whether aggressive lowering of blood pressure improves long-term transplant outcome will have to be studied prospectively.
- Published
- 1998
- Full Text
- View/download PDF
46. The humoral immune response towards HLA class II determinants in renal transplantation.
- Author
-
Feucht HE and Opelz G
- Subjects
- Antibody Formation immunology, HLA-DR Antigens immunology, Humans, Antibody Formation physiology, HLA-DR Antigens physiology, Kidney Transplantation immunology
- Published
- 1996
- Full Text
- View/download PDF
47. Identification of complement activation sites in human immunodeficiency virus type-1 glycoprotein gp120.
- Author
-
Süsal C, Kirschfink M, Kröpelin M, Daniel V, and Opelz G
- Subjects
- Amino Acid Sequence, Binding Sites, Complement C1q metabolism, Complement C3 metabolism, Complement C4 metabolism, Complement C5 metabolism, Complement C9 metabolism, HIV Envelope Protein gp120 chemistry, HIV Envelope Protein gp120 metabolism, HIV Infections physiopathology, Humans, Molecular Sequence Data, Mononuclear Phagocyte System physiopathology, Peptide Fragments chemistry, Peptide Fragments metabolism, Peptide Fragments pharmacology, Properdin metabolism, Complement Activation drug effects, HIV Envelope Protein gp120 pharmacology, HIV-1 physiology
- Abstract
Recombinant glycoprotein 120 (rgp120) of human immunodeficiency virus type-1 (HIV-1) activates the human complement system in the absence of anti-gp120 antibodies. HIV-1 glycoprotein gp120 can dissociate from the viral envelope either spontaneously or after binding of HIV-1 to the CD4 molecule. As a consequence, gp120 can circulate in the patient's serum and attach to the surface of uninfected CD4+ T cells. Complement activation by cell-bound HIV-1 glycoprotein gp120 with subsequent opsonization may represent a mechanism for the elimination of uninfected CD4+ cells by the reticuloendothelial system, thereby enhancing the progression of HIV disease. In the current study, the complement proteins C4,C3,C5,C9, and properdin were found to bind to a synthetic peptide covering positions 233-251 of the gp120BRU sequence on incubation with normal human serum. Complement activation by the peptide was comparable with that induced by aggregated IgG, complete rgp120, and the previously described complement-activating gp41-peptide 609-623. Activation occurred via the classical pathway and was abrogated in the presence of EDTA, Mg2+/EGTA, or C4-deficient human serum. Peptides partly overlapping the sequence 233-251 activated complement to a lesser extent. The complement-activating capacity of the gp120 sequence 233-251 was not restricted to the HIV-1BRU isolate, because a peptide from the corresponding sequence of the HIV-1MN strain was also capable of activating complement. An additional strong complement-activating site was identified in the gp120 sequence 321-360 of the HIV-1MN strain. These data indicate that distinct sites in gp120 are able to activate human serum complement via the classical pathway in the absence of anti-gp120 and independent of glycosylation.
- Published
- 1996
48. Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation.
- Author
-
Stewart T, Tsai SC, Grayson H, Henderson R, and Opelz G
- Subjects
- Adult, Azathioprine therapeutic use, Cohort Studies, Cyclosporine therapeutic use, Europe epidemiology, Female, Follow-Up Studies, Humans, Immunosuppressive Agents therapeutic use, Incidence, Logistic Models, Middle Aged, North America epidemiology, Risk, Risk Factors, Steroids therapeutic use, Breast Neoplasms epidemiology, Heart Transplantation statistics & numerical data, Immunosuppression Therapy statistics & numerical data, Kidney Transplantation statistics & numerical data
- Abstract
In mice, retrovirus-associated breast cancers are promoted by immune mechanisms, and immunosuppression during the premalignant phase reduces the incidence of breast cancer and prolongs life. If some women likewise have immune promotion of breast cancer, the incidence of breast cancer in patients receiving therapeutic immunosuppression should be lower than that in a comparable cohort of non-immunosuppressed women. We examined the incidence of de-novo breast cancer arising in women receiving immunosuppressive therapy after kidney or heart transplantation, comparing the figures with published rates. In 25,914 immunosuppressed women followed for 1-11 years there were 86 cases of breast cancer compared with 113.8 expected (p = 0.009). Incidence was particularly low in the first transplant year with relative risk 0.49, rising to 0.84 in subsequent years. For all other major cancers the incidence was higher in the immunosuppressed women. If, as in mice, the reduced incidence of breast cancer is a direct effect of immunosuppression, these observations raise the possibility of therapeutic manipulation of specific immune mechanisms that promote tumour growth.
- Published
- 1995
- Full Text
- View/download PDF
49. Conversion from cyclosporin to azathioprine after kidney transplantation.
- Author
-
Opelz G
- Subjects
- Drug Therapy, Combination, Graft Survival drug effects, Humans, Immunosuppression Therapy methods, Retrospective Studies, Steroids therapeutic use, Azathioprine therapeutic use, Cyclosporine therapeutic use, Kidney Transplantation immunology
- Published
- 1995
50. Striking inverse correlation between IgG anti-F(ab')2 and autoantibody production in patients with cold agglutination.
- Author
-
Terness P, Kirschfink M, Navolan D, Dufter C, Kohl I, Opelz G, and Roelcke D
- Subjects
- Agglutinins blood, Anemia, Hemolytic, Autoimmune blood, Anemia, Hemolytic, Autoimmune complications, Antibodies, Anti-Idiotypic blood, Antibodies, Bacterial blood, Antibodies, Bacterial immunology, Antibodies, Viral blood, Antibodies, Viral immunology, Antibody Specificity, Autoimmune Diseases blood, Autoimmune Diseases complications, B-Lymphocyte Subsets immunology, Convalescence, Cryoglobulins, Herpesviridae Infections complications, Herpesvirus 4, Human, Humans, Immunoglobulin Fab Fragments blood, Immunoglobulin G blood, Immunoglobulin M blood, Immunoglobulin M immunology, Pneumonia, Mycoplasma complications, Tumor Virus Infections complications, Agglutinins immunology, Anemia, Hemolytic, Autoimmune immunology, Antibodies, Anti-Idiotypic immunology, Autoimmune Diseases immunology, Immunoglobulin Fab Fragments immunology, Immunoglobulin G immunology
- Abstract
Previous experiments showed that the physiologic IgG anti-F(ab')2 antibody suppresses the response of human autoreactive B cells. In the present study, we analyzed the IgG anti-F(ab')2 antibody in 293 patients with cold agglutination (CA). Their average IgG anti-F(ab')2 titer was not much different (211 +/- 8.3) from that of 279 healthy persons (195 +/- 6.7). However, CA patients with high anti-F(ab')2 titers had low CA autoantibody titers and vice versa (P = .0028; rho = -0.175). The stratification of patients according to the auto-antibody's specificity (anti-I, anti-i, anti-Pr) showed an inverse correlation between anti-F(ab')2 and CA in the anti-I group (P = .0057; rho = -0.180). Interestingly, the association was present only in patients whose disease was caused by noninfectious agents (P < .0001; rho = -0.423). The inverse correlation argues for an important role of the IgG anti-F(ab')2 in the regulation of autoantibody production in CA patients.
- Published
- 1995
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.